Target Name: SELPLG
NCBI ID: G6404
Other Name(s): CD162 antigen | SELPL_HUMAN | selectin P ligand | PSGL1 | P-selectin glycoprotein ligand 1 | CLA | Selectin P ligand | SELPLG variant 1 | Cutaneous lymphocyte-associated associated antigen | P-selectin glycoprotein ligand 1 (isoform 1) | cutaneous lymphocyte-associated associated antigen | SELPLG variant 2 | PSGL-1 | PGSL-1 | Selectin P ligand, transcript variant 1 | CD162 | Selectin P ligand, transcript variant 2 | P-selectin glycoprotein ligand 1 (isoform 2)

SELPLG: A Potential Drug Target for Various Diseases

SELPLG (CD162 antigen) is a protein that is expressed in various tissues throughout the body, including the skin, hair, and nails. It is a member of the integrin family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. SELPLG has been shown to have various functions throughout the body, including cell adhesion, migration, and invasion.

One of the unique features of SELPLG is its ability to interact with integrin alpha-2 (ITGA-2), a protein that is also known as CD162. This interaction between SELPLG and ITGA-2 has been shown to play a critical role in the development and progression of various diseases, including cancer.

SELPLG has been shown to be a potential drug target in various settings. For example, studies have shown that inhibiting SELPLG can lead to a decrease in the growth and survival of cancer cells that express high levels of ITGA-2. Additionally, SELPLG has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

SELPLG has also been shown to be involved in the regulation of inflammation and immune response. Studies have shown that SELPLG can interact with various immune cells, including T cells and macrophages, and that this interaction plays a critical role in the regulation of immune response and inflammation.

In conclusion, SELPLG is a protein that has been shown to have various functions throughout the body, including cell adhesion, migration, and invasion. Its interaction with ITGA-2 has also been shown to play a critical role in the development and progression of various diseases, including cancer. Additionally, SELPLG has been shown to be involved in the regulation of inflammation and immune response. Given these findings, SELPLG is a potential drug target for the treatment of various diseases.

Protein Name: Selectin P Ligand

Functions: A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture

More Common Targets

SEM1 | SEM1P1 | SEMA3A | SEMA3B | SEMA3B-AS1 | SEMA3C | SEMA3D | SEMA3E | SEMA3F | SEMA3G | SEMA4A | SEMA4B | SEMA4C | SEMA4D | SEMA4F | SEMA4G | SEMA5A | SEMA5A-AS1 | SEMA5B | SEMA6A | SEMA6A-AS1 | SEMA6A-AS2 | SEMA6B | SEMA6C | SEMA6D | SEMA7A | Semenogelin | SEMG1 | SEMG2 | SENCR | SENP1 | SENP2 | SENP3 | SENP3-associated complex | SENP3-EIF4A1 | SENP5 | SENP6 | SENP7 | SENP8 | SEPHS1 | SEPHS1P4 | SEPHS1P6 | SEPHS2 | SEPSECS | SEPSECS-AS1 | SEPT5-GP1BB | SEPTIN1 | SEPTIN10 | SEPTIN11 | SEPTIN12 | SEPTIN14 | SEPTIN2 | SEPTIN3 | SEPTIN4 | SEPTIN4-AS1 | SEPTIN5 | SEPTIN6 | SEPTIN7 | SEPTIN7-DT | SEPTIN7P11 | SEPTIN7P14 | SEPTIN7P2 | SEPTIN7P6 | SEPTIN7P9 | SEPTIN8 | SEPTIN9 | SERAC1 | SERBP1 | SERBP1P3 | SERF1A | SERF1B | SERF2 | SERF2-C15ORF63 | SERGEF | SERHL | SERINC1 | SERINC2 | SERINC3 | SERINC4 | SERINC5 | Serine (or cysteine) proteinase inhibitor clade F | Serine palmitoyltransferase | Serine protease | Serine protease inhibitor | Serine-aspartate repeat-containing protein I-like | SERP1 | SERP2 | SERPINA1 | SERPINA10 | SERPINA11 | SERPINA12 | SERPINA13P | SERPINA2 | SERPINA3 | SERPINA4 | SERPINA5 | SERPINA6 | SERPINA7 | SERPINA9 | SERPINB1